Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07447817) titled 'Selinexor and Pacritinib in JAK Inhibitor-naive MF Patients With Cytopenias' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: John Mascarenhas
Condition:
Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Intervention:
Drug: Pacritinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 4, 2026
Target Sample Size: 26
Countries of Recruitment:
United States
To know more, visit https://clinical...